Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019

BOSTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the company’s nonalcoholic steatohepatitis (NASH) research and development program, including studies evaluating machine learning approaches to the interpretation of liver histology, noninvasive tests (NITs) for the characterization and monitoring of disease severity, and novel therapies for the treatment of this disease. The data are being presented at The Liver Meeting® 2019 in Boston this week. “By co

Click to view original post